Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05146297 · ClinicalTrials.gov registry record · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
A NA study of Breast Cancer and Prostate Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 644
- Enrollment target
- 3
- Study locations
NCT05146297 is a NA study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 644 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05146297, a NA study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 644 participants
- Enrollment target
- 3
- Study locations
Study Summary
This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity \& IncluSion in Research Underpinning Prevention \& Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experienced by BIPOC, the research team propose three integrated and synergistic aims to improve diversity and inclusion in CTs through disruptive approaches at the community (Aim 1), provider, system and patient (Aim 2), and basic and translational scientist levels (Aim 3). All three aims focus on metrics for changing norms reified in institutional policies and established practice that will provide essential evidence to translate and scale these changes to institutions and networks involved in cancer treatment research. In Aim 1, the research team will partner with local organizations to formulate and disseminate new norms regarding cancer care and research and diffuse these new norms throughout the community via community organizations and Health Ambassadors bringing a different vantage point on CTs, raising awareness and increasing demand for access to cancer research. In Aim 2, the research team will create an electronic approach to identify key clinical characteristics of patients and trials and match patients and trials and bring these data to patients and their physicians at the time of key decisions. In Aim 3, the research team will provide and integrate essential experiential training in diversity, social determinants of health and the importance of conducting community-relevant work into basic and translational science training. This DISRUPT proposal provides the foundation to disrupt norms about cancer clinical trials in our communities, delivery systems and scientific re
Conditions Studied
Interventions
- BEHAVIORAL Clinical trial match-list
- BEHAVIORAL Match-list intervention
Study Locations (3)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Herbert Irving Comprehensive Cancer Care Center - New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2023-04-23 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05146297
The ClinicalTrials.gov registry entry for NCT05146297 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Clinical trial match-list is the first listed.
NCT05146297 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05146297 about?
NCT05146297 is a clinical study titled "Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials". This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative res...
What is the current status of trial NCT05146297?
This trial is currently recruiting. It is a NA study. The enrollment target is 644 participants. The study started on 2023-04-23. Estimated completion is 2026-03.
What conditions does trial NCT05146297 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Liver Cancer.
What interventions are being tested in trial NCT05146297?
The interventions under investigation include: Clinical trial match-list (BEHAVIORAL), Match-list intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05146297?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05146297 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.